Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
PaperCitations, authors & open-access status
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 347 citations, 2011 year and green oa status.
347
Citations
2011
Year
green
OA Status